2021

1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

   Blood, Vol. 137, Núm. 1, pp. 49-60

2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

   Blood, Vol. 138, Núm. 17, pp. 1583-1589